Eli Lilly and Company & South Korea

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

South Korea: South Korea's stock market, particularly the KOSPI, experienced significant gains due to strong performance in its technology sector, driven by companies like Samsung Electronics and SK Hynix, and the broader AI boom.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.

South Korea: South Korean banks held $6 billion of frozen Iranian funds, which were later transferred to Qatar>>> pending a prisoner release, highlighting its role in the initial fund freezing.

Eli Lilly and Company: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.

South Korea: South Korea is the home country of Hanmi Pharm. Co., Ltd. and is excluded from Eli Lilly and Company's exclusive commercialization rights for sonefpeglutide.